PT - JOURNAL ARTICLE AU - Vicco, Anna AU - McCormack, Clare AU - Pedrique, Belen AU - Ribeiro, Isabela AU - Malavige, Gathsaurie Neelika AU - Dorigatti, Ilaria TI - A scoping literature review of global dengue age-stratified seroprevalence data: estimating dengue force of infection in endemic countries AID - 10.1101/2023.04.07.23288290 DP - 2023 Jan 01 TA - medRxiv PG - 2023.04.07.23288290 4099 - http://medrxiv.org/content/early/2023/04/07/2023.04.07.23288290.short 4100 - http://medrxiv.org/content/early/2023/04/07/2023.04.07.23288290.full AB - Dengue poses a significant burden worldwide, and a more comprehensive understanding of the heterogeneity in the intensity of dengue transmission within endemic countries is necessary to evaluate the potential impact of public health interventions.This scoping literature review aimed to update a previous study of dengue transmission intensity by collating global age-stratified dengue seroprevalence data published in the Medline and Embase databases from 2014 to 2022. These data were then utilized to calibrate catalytic models and estimate the force of infection (FOI), which is the yearly per-capita risk of infection for a typical susceptible individual.We found a total of 44 new publications containing 47 relevant datasets across 20 endemic countries. Together with the previously available average FOI estimates, there are now 280 dengue average FOI estimates obtained from seroprevalence data and 149 estimates obtained from case-notification data available across the world.The results showed large heterogeneities in average dengue FOI both across and within countries. These new estimates can be used to inform ongoing modelling efforts to improve our understanding of the drivers of heterogeneity in dengue transmission globally, which in turn can help inform the optimal implementation of public health interventions.Author summary In this work, we conducted a scoping literature review to collate global dengue age-specific seroprevalence data from dengue endemic areas published between 2014 and 2022. These data were used to calibrate mathematical models and estimate the average yearly force of infection (FOI), which is a fundamental measure of transmission intensity. FOI estimates can be used to quantify the risk of infection, disease burden and the potential impact of new interventions, such as vaccination.In addition, the FOI estimates generated in this study contribute to ongoing efforts to better characterise and map dengue transmission intensity worldwide.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCM and ID acknowledge funding from the Drugs for Neglected Diseases initiative and the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union. ID acknowledges research funding from a Sir Henry Dale Fellowship funded by the Royal Society and Wellcome Trust (grant 213494/Z/18/Z). AV thanks the Foundation Blanceflor Boncompagni Ludovisi (Sweaden) for funding her PhD visiting period at Imperial College London. DNDi thanks the French Development Agency (AFD), France; Medecins Sans Frontieres International; Swiss Agency for Development and Cooperation (SDC), Switzerland; UK aid, UK; for the financial support in this work. The findings and conclusions contained herein are those of the authors and do not necessarily reflect positions or policies of the aforementioned funding bodies.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used ONLY openly available human data retrieved by published papers.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.